Moderna MRNA Net product sales — Contract with Customer, Liability
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Moderna in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiability.
The official record: Moderna’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →
Ask your AI about Moderna's net product sales — contract with customer, liability.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Moderna's net product sales — contract with customer, liability?
- Moderna (MRNA) reported net product sales — contract with customer, liability of $95M in Q1 2026.
- How has Moderna's net product sales — contract with customer, liability changed year-over-year?
- Moderna's net product sales — contract with customer, liability decreased by 38.3% year-over-year, from $154M to $95M.
- What is the long-term trend for Moderna's net product sales — contract with customer, liability?
- Over 4 years (2021 to 2025), Moderna's net product sales — contract with customer, liability has grown at a -61.9% compound annual growth rate (CAGR), from $29.71B to $626M.
- What does net product sales — contract with customer, liability mean?
- This represents the total outstanding liability balance related to customer contracts, including provisions for variable consideration such as rebates, discounts, and expected returns. It serves as a contra-revenue account that adjusts gross product sales to arrive at net revenue. A high balance indicates significant future obligations or potential revenue reversals associated with current and past sales.